CNBX Pharmaceuticals Inc.

OTCPK:CNBX Stock Report

Market Cap: US$317.3k

CNBX Pharmaceuticals Valuation

Is CNBX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CNBX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CNBX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CNBX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CNBX?

Key metric: As CNBX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CNBX. This is calculated by dividing CNBX's market cap by their current revenue.
What is CNBX's PS Ratio?
PS Ratio1.4x
SalesUS$230.07k
Market CapUS$317.34k

Price to Sales Ratio vs Peers

How does CNBX's PS Ratio compare to its peers?

The above table shows the PS ratio for CNBX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.9x
SEEL.Q Seelos Therapeutics
0.06xn/aUS$130.8k
KOAN Resonate Blends
0.7xn/aUS$502.0k
GSAC GelStat
5.6xn/aUS$1.2m
BSPK Bespoke Extracts
1.1xn/aUS$1.2m
CNBX CNBX Pharmaceuticals
1.4xn/aUS$317.3k

Price-To-Sales vs Peers: CNBX is good value based on its Price-To-Sales Ratio (1.4x) compared to the peer average (1.9x).

Price to Sales Ratio vs Industry

How does CNBX's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

73 CompaniesPrice / SalesEstimated GrowthMarket Cap
OGN Organon
0.6x-0.06%US$3.94b
PRGO Perrigo
0.9x3.4%US$3.83b
BHC Bausch Health Companies
0.3x1.5%US$2.93b
AMRX Amneal Pharmaceuticals
1x5.6%US$2.60b
CNBX 1.4xIndustry Avg. 2.6xNo. of Companies73PS048121620+
73 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: CNBX is good value based on its Price-To-Sales Ratio (1.4x) compared to the US Pharmaceuticals industry average (2.6x).

Price to Sales Ratio vs Fair Ratio

What is CNBX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CNBX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.4x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate CNBX's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

7D

5.3%

1Y

17.0%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$56.91

7D

0.6%

1Y

9.8%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.82

7D

4.7%

1Y

-4.8%